121 related articles for article (PubMed ID: 29412654)
1. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
2. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of topoisomerase I poisoning by a camptothecin analog.
Staker BL; Hjerrild K; Feese MD; Behnke CA; Burgin AB; Stewart L
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15387-92. PubMed ID: 12426403
[TBL] [Abstract][Full Text] [Related]
4. Binding of topotecan to chromatin: Insights into cooperative binding and comparison with DNA.
Babaei M; Rabbani-Chadegani A; Ghadam P
Int J Biol Macromol; 2015 Sep; 80():57-63. PubMed ID: 26092169
[TBL] [Abstract][Full Text] [Related]
5. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].
Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Kudelina IA; Zhuze AL
Mol Biol (Mosk); 2002; 36(5):912-30. PubMed ID: 12391856
[TBL] [Abstract][Full Text] [Related]
6. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
7. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
8. The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
Koosha F; Neshasteh-Riz A; Takavar A; Eyvazzadeh N; Mazaheri Z; Eynali S; Mousavi M
Biochem Biophys Res Commun; 2017 Sep; 491(4):1092-1097. PubMed ID: 28797568
[TBL] [Abstract][Full Text] [Related]
9. DNA binding induces conformational transition within human DNA topoisomerase I in solution.
Oleinikov V; Sukhanova A; Mochalov K; Ustinova O; Kudelina I; Bronstein I; Nabiev I
Biopolymers; 2002; 67(6):369-75. PubMed ID: 12209444
[TBL] [Abstract][Full Text] [Related]
10. [Interaction of topotecan-a DNA topoisomerase I inhibitor-with dual-stranded polydeoxyribonucleotides. V. Topotecan is able to cause single- and double-strand breaks in ring superhelical DNA in the absence of enzyme].
Grokhovskiĭ SL; Strel'tsov SA; Zhuze AL
Mol Biol (Mosk); 2003; 37(6):1045-54. PubMed ID: 14714500
[TBL] [Abstract][Full Text] [Related]
11. [Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].
Strel'tsov SA; Grokhovskiĭ SL; Kudelina IA; Oleĭnikov VA; Zhuze AL
Mol Biol (Mosk); 2001; 35(3):432-41. PubMed ID: 11443925
[TBL] [Abstract][Full Text] [Related]
12. Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study.
Bailly C; Vergoten G
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838813
[TBL] [Abstract][Full Text] [Related]
13. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
Mancini G; D'Annessa I; Coletta A; Sanna N; Chillemi G; Desideri A
PLoS One; 2010 Jun; 5(6):e10934. PubMed ID: 20532182
[TBL] [Abstract][Full Text] [Related]
14. Structural spectroscopy and dynamics of inter- and intramolecular H-bonding interactions of topotecan, a potent anticancer drug, in organic solvents and in aqueous solution.
di Nunzio MR; Wang Y; Douhal A
J Phys Chem B; 2012 Jun; 116(25):7522-30. PubMed ID: 22662747
[TBL] [Abstract][Full Text] [Related]
15. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
16. Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.
Streltsov S; Oleinikov V; Ermishov M; Mochalov K; Sukhanova A; Nechipurenko Y; Grokhovsky S; Zhuze A; Pluot M; Nabiev I
Biopolymers; 2003; 72(6):442-54. PubMed ID: 14587067
[TBL] [Abstract][Full Text] [Related]
17. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I.
Yao S; Murali D; Seetharamulu P; Haridas K; Petluru PN; Reddy DG; Hausheer FH
Cancer Res; 1998 Sep; 58(17):3782-6. PubMed ID: 9731484
[TBL] [Abstract][Full Text] [Related]
18. Topotecan dynamics, tautomerism and reactivity--1H/13C NMR and ESI MS study.
Hyz K; Kawecki R; Bednarek E; Bocian W; Sitkowski J; Kozerski L
Magn Reson Chem; 2010 Aug; 48(8):575-84. PubMed ID: 20623719
[TBL] [Abstract][Full Text] [Related]
19. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
20. [Interaction of topotecan--a DNA topoisomerase I inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan].
strel'tsov SA; Mikheĭkin AL; Nechipurenko IuD
Mol Biol (Mosk); 2001; 35(3):442-50. PubMed ID: 11443926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
